Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study.
Paper
Loaded from Europe PMC by your browser; OSCR does not store it: doi.org · Europe PMC
The paper is loaded when this pane is shown.
The authors' code
R · 211 lines · 6 KB · no license
- #Augmentation
- install.packages("heemod")
- library(heemod)
- pacman::p_load(data.table, dplyr)
- # define parameters
- par_mod <- define_parameters(
- c_3rdOP = 1165,
- c_4thOP = 1341,
- c_5thOP = 1686,
- c_3rdIP = 405,
- c_4thIP = 405,
- c_5thIP = 572,
- c_SOPC = 1190,
- c_AUG = 109,
- u_remission = 0.85,
- u_response = 0.72,
- u_nresponse = 0.58,
- u_tx = 0.58,
- p_3rdTX2RES = 0.186,
- p_3rdTX2REM = 0.198,
- p_3rdRES2REL = 0.281,
- p_3rdREM2REL = 0.125,
- p_4thTX2RES = 0.109,
- p_4thTX2REM = 0.1,
- p_4thRES2REL = 0.359,
- p_4thREM2REL = 0.126,
- p_5thTX2RES = 0.081,
- p_5thTX2REM = 0.073,
- p_5thRES2REL = 0.38,
- p_5thREM2REL = 0.228,
- rr_AUG_remission = 1.28,
- rr_AUG_response = 1.27,
- rr_AUG_rem2rel = 1,
- rr_AUG_res2rel = 1,
- d_rate = 0.03,
- p_death = case_when(
- model_time <= 13 ~ 0.001772008, # cycle 1-13
- model_time >= 14 & model_time <= 26 ~ 0.000921875, # cycle 14-26
- model_time >= 27 & model_time <= 39 ~ 0.000706614, # cycle 27-39
- model_time >= 40 & model_time <= 52 ~ 0.000590032, # cycle 40-52
- model_time >= 53 ~ 0.000513965 # cycle after 53
- )
- )
- discount_cost <- function(value, rate, cycle) {
- year <- case_when(
- cycle <= 13 ~ 1, # y1
- cycle >= 14 & cycle <= 26 ~ 2, # y2
- cycle >= 27 & cycle <= 39 ~ 3, # y3
- cycle >= 40 & cycle <= 52 ~ 4, # y4
- cycle >= 53 & cycle <= 65 ~ 5 # y5
- )
- # discount
- ifelse(year == 1,
- value, # did not discount at Y1
- value / (1 + rate)^(year - 1) # other years
- )
- }
- discount_qaly <- function(value, rate, cycle) {
- year <- case_when(
- cycle <= 13 ~ 1, # y1
- cycle >= 14 & cycle <= 26 ~ 2, # y2
- cycle >= 27 & cycle <= 39 ~ 3, # y3
- cycle >= 40 & cycle <= 52 ~ 4, # y4
- cycle >= 53 & cycle <= 65 ~ 5 # y5
- )
- # discount
- ifelse(year == 1,
- value/13, # did not discount at Y1
- value/ 13 / (1 + rate)^(year - 1) # other years
- )
- }
- # define states
- mat_antidepressant <- define_transition(
- state_names = c("3rd_TX", "3rd_Response", "3rd_Remission", "3rd_Nresponse",
- "4th_TX", "4th_Response", "4th_Remission", "4th_Nresponse",
- "5th_TX", "5th_Response", "5th_Remission", "5th_Nresponse",
- "Death"),
- # from 3rd_TX
- 0, p_3rdTX2RES*rr_AUG_response, p_3rdTX2REM*rr_AUG_remission, (1 - p_3rdTX2RES*rr_AUG_response - p_3rdTX2REM*rr_AUG_remission - p_death), 0, 0, 0, 0, 0, 0, 0, 0, p_death,
- # from 3rd_Response
- 0, (1 - p_3rdRES2REL*rr_AUG_res2rel - p_death), 0, 0, p_3rdRES2REL*rr_AUG_res2rel, 0, 0, 0, 0, 0, 0, 0, p_death,
- # from 3rd_Remission
- 0, 0, (1 - p_3rdREM2REL*rr_AUG_rem2rel - p_death), 0, p_3rdREM2REL*rr_AUG_rem2rel, 0, 0, 0, 0, 0, 0, 0, p_death,
- # from 3rd_Nresponse
- 0, 0, 0, 0, (1 - p_death), 0, 0, 0, 0, 0, 0, 0, p_death,
- # from 4th_TX
- 0, 0, 0, 0, 0, p_4thTX2RES, p_4thTX2REM, (1 - p_4thTX2RES - p_4thTX2REM - p_death), 0, 0, 0, 0, p_death,
- # from 4th_Response
- 0, 0, 0, 0, 0, (1 - p_4thRES2REL - p_death), 0, 0, p_4thRES2REL, 0, 0, 0, p_death,
- # from 4th_Remission
- 0, 0, 0, 0, 0, 0, (1 - p_4thREM2REL - p_death), 0, p_4thREM2REL, 0, 0, 0, p_death,
- # from 4th_Nresponse
- 0, 0, 0, 0, 0, 0, 0, 0, (1 - p_death), 0, 0, 0, p_death,
- # from 5th_TX
- 0, 0, 0, 0, 0, 0, 0, 0, 0, p_5thTX2RES, p_5thTX2REM, (1 - p_5thTX2RES - p_5thTX2REM - p_death), p_death,
- # from 5th_Response
- 0, 0, 0, 0, 0, 0, 0, 0, p_5thRES2REL, (1 - p_5thRES2REL - p_death), 0, 0, p_death,
- # from 5th_Remission
- 0, 0, 0, 0, 0, 0, 0, 0, p_5thREM2REL, 0, (1 - p_5thREM2REL - p_death), 0, p_death,
- # from 5th_Nresponse
- 0, 0, 0, 0, 0, 0, 0, 0, (1 - p_death), 0, 0, 0, p_death,
- # from Death
- 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1)
- # define strategy
- mod_antidepressant <- define_strategy(
- transition = mat_antidepressant,
- "3rd_TX" = define_state(
- cost = discount_cost(c_SOPC + c_3rdOP + c_3rdIP + c_AUG, d_rate, model_time),
- QALY = discount_qaly(u_tx, d_rate, model_time)
- ),
- "4th_TX" = define_state(
- cost = discount_cost(c_4thOP + c_4thIP, d_rate, model_time),
- QALY = discount_qaly(u_tx, d_rate, model_time)
- ),
- "5th_TX" = define_state(
- cost = discount_cost(c_5thOP + c_5thIP, d_rate, model_time),
- QALY = discount_qaly(u_tx, d_rate, model_time)
- ),
- "3rd_Response" = define_state(
- cost = discount_cost(c_SOPC + c_3rdOP + c_AUG, d_rate, model_time),
- QALY = discount_qaly(u_response, d_rate, model_time)
- ),
- "4th_Response" = define_state(
- cost = discount_cost(c_4thOP, d_rate, model_time),
- QALY = discount_qaly(u_response, d_rate, model_time)
- ),
- "5th_Response" = define_state(
- cost = discount_cost(c_5thOP, d_rate, model_time),
- QALY = discount_qaly(u_response, d_rate, model_time)
- ),
- "3rd_Remission" = define_state(
- cost = discount_cost(c_SOPC + c_3rdOP + c_AUG, d_rate, model_time),
- QALY = discount_qaly(u_remission, d_rate, model_time)
- ),
- "4th_Remission" = define_state(
- cost = discount_cost(c_4thOP, d_rate, model_time),
- QALY = discount_qaly(u_remission, d_rate, model_time)
- ),
- "5th_Remission" = define_state(
- cost = discount_cost(c_5thOP, d_rate, model_time),
- QALY = discount_qaly(u_remission, d_rate, model_time)
- ),
- "3rd_Nresponse" = define_state(
- cost = discount_cost(c_3rdOP + c_3rdIP, d_rate, model_time),
- QALY = discount_qaly(u_nresponse, d_rate, model_time)
- ),
- "4th_Nresponse" = define_state(
- cost = discount_cost(c_4thOP + c_4thIP, d_rate, model_time),
- QALY = discount_qaly(u_nresponse, d_rate, model_time)
- ),
- "5th_Nresponse" = define_state(
- cost = discount_cost(c_5thOP + c_5thIP, d_rate, model_time),
- QALY = discount_qaly(u_nresponse, d_rate, model_time)
- ),
- "Death" = define_state(
- cost = 0,
- QALY = 0
- )
- )
- # run model
- result <- run_model(
- mod = mod_antidepressant,
- parameters = par_mod,
- cycles = 65,
- cost = cost,
- effect = QALY,
- method = "beginning",
- init = c(1000, rep(0, 12)) # 1000 people
- )
- state_counts <- get_counts(result)
- print(state_counts, n=1000)
- cost_by_cycle <- get_values(result)
- print(cost_by_cycle)
- print(cost_by_cycle)
- print(qaly_by_cycle)
- print(result$run_model$cost)
- print(result$run_model$QALY)
AUG.R at commit b2ba672, no license · at the source
Overview
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
- Department of Global and Environmental Health, School of Global Public Health, New York University, New York, New York, United States of America
- Department of Pharmacy, The University of Hong Kong–Shenzhen Hospital, Hong Kong SAR, China
- Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
- Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
- Department of Medicine, The University of Hong Kong–Shenzhen Hospital, Hong Kong SAR, China
Abstract
Background: Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of esketamine versus multiple alternative third-line strategies for TRD from the Hong Kong healthcare payer’s perspective.
Methods and findings: A Markov cohort model simulated adults with TRD in Hong Kong over 5 years with 4-week cycles. The model compared esketamine plus AD with six alternative third-line treatment strategies: combination therapy (AD plus AD), augmentation therapy (AD plus antipsychotic or lithium), psychotherapy alone, psychotherapy plus AD, repetitive transcranial magnetic stimulation (rTMS) plus AD, and electroconvulsive therapy (ECT) plus AD. Primary outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) under a US$50,000/
Conclusions: Esketamine appeared more cost-effective than rTMS and ECT, but not cost-effective compared with other commonly used third-line treatment strategies for TRD. These findings suggest that cost-effectiveness evidence may help inform more context-sensitive treatment sequencing strategies beyond conventional line-of-therapy frameworks. Policy approaches such as price negotiation, optimized service delivery, and alternative dosing strategies may improve the value of esketamine for TRD management.
Reproduced under the paper's license (CC BY), from the paper cited above.
Repositories
Its files are read in the Code ↔ Paper reader above.
scan2030/scan2030-WP-3_TRD_ESK_CEA
b2ba6724951638f2459efcd96a502f9f46926811, 11 April 2026Availability: 1 check, the latest on 29 September 2026: the link answers
- 29 September 2026: the link answers
29 files
- Basecase/
AUG.R , R, 211 lines - Basecase/
CEA_Plane.R , R, 151 lines - Basecase/
COM.R , R, 211 lines - Basecase/
ECT.R , R, 225 lines - Basecase/
ESK_Basecase.R , R, 234 lines - Basecase/
TMS.R , R, 223 lines - Basecase/
cPSY.R , R, 221 lines - Basecase/
mPSY.R , R, 225 lines - Scenario Analysis/
AUG_20yrs.R , R, 276 lines - Scenario Analysis/
COM_20yrs.R , R, 255 lines - Scenario Analysis/
ECT_20yrs.R , R, 266 lines - Scenario Analysis/
ESK_S1.R , R, 246 lines - Scenario Analysis/
ESK_S2.R , R, 239 lines - Scenario Analysis/
ESK_S3.R , R, 239 lines - Scenario Analysis/
ESK_S4.R , R, 235 lines - Scenario Analysis/
ESK_S5.R , R, 230 lines - Scenario Analysis/
ESK_S6.R , R, 232 lines - Scenario Analysis/
ESK_S7.R , R, 276 lines - Scenario Analysis/
TMS_20yrs.R , R, 268 lines - Scenario Analysis/
cPSY_20yrs.R , R, 266 lines - Scenario Analysis/
mPSY_20yrs.R , R, 265 lines - Sensitivity Analysis/
PSA_final.R , R, 1,391 lines - Sensitivity Analysis/
SA_AUG.R , R, 521 lines - Sensitivity Analysis/
SA_COM.R , R, 524 lines - Sensitivity Analysis/
SA_ECT.R , R, 544 lines - Sensitivity Analysis/
SA_TMS.R , R, 560 lines - Sensitivity Analysis/
SA_cPSY.R , R, 543 lines - Sensitivity Analysis/
SA_mPSY.R , R, 540 lines - README.md, Text, 81 lines
Zenodo 19520620
Availability: 1 check, the latest on 29 September 2026: the link answers (HTTP 200)
- 29 September 2026: the link answers (HTTP 200)
29 files
- Basecase/
AUG.R , R, 211 lines - Basecase/
CEA_Plane.R , R, 151 lines - Basecase/
COM.R , R, 211 lines - Basecase/
ECT.R , R, 225 lines - Basecase/
ESK_Basecase.R , R, 234 lines - Basecase/
TMS.R , R, 223 lines - Basecase/
cPSY.R , R, 221 lines - Basecase/
mPSY.R , R, 225 lines - Scenario Analysis/
AUG_20yrs.R , R, 276 lines - Scenario Analysis/
COM_20yrs.R , R, 255 lines - Scenario Analysis/
ECT_20yrs.R , R, 266 lines - Scenario Analysis/
ESK_S1.R , R, 246 lines - Scenario Analysis/
ESK_S2.R , R, 239 lines - Scenario Analysis/
ESK_S3.R , R, 239 lines - Scenario Analysis/
ESK_S4.R , R, 235 lines - Scenario Analysis/
ESK_S5.R , R, 230 lines - Scenario Analysis/
ESK_S6.R , R, 232 lines - Scenario Analysis/
ESK_S7.R , R, 276 lines - Scenario Analysis/
TMS_20yrs.R , R, 268 lines - Scenario Analysis/
cPSY_20yrs.R , R, 266 lines - Scenario Analysis/
mPSY_20yrs.R , R, 265 lines - Sensitivity Analysis/
PSA_final.R , R, 1,391 lines - Sensitivity Analysis/
SA_AUG.R , R, 521 lines - Sensitivity Analysis/
SA_COM.R , R, 524 lines - Sensitivity Analysis/
SA_ECT.R , R, 544 lines - Sensitivity Analysis/
SA_TMS.R , R, 560 lines - Sensitivity Analysis/
SA_cPSY.R , R, 543 lines - Sensitivity Analysis/
SA_mPSY.R , R, 540 lines - README.md, Text, 81 lines
The paper's code and data availability statement is in the Data section.
Tracing map
Proposed by the machine: these links were found in the paper and verified at the source, without human review. The map will receive a Zenodo DOI once one of the paper's authors has validated it with their ORCID.
What the map holds:
- 2 repositories of the authors' code, each at its verified commit, with its license and how the link was found in the paper;
- 56 scripts, each with its path and the digest of its content;
- no match between paragraphs and code yet;
- neither the text of the paper nor the code itself.
Its JSON (tracing-map.json) is deposited on Zenodo with its DOI once the map is validated.
Data
No dataset and no data link were found in the paper.
Data Availability
The data used in this study cannot be shared publicly because the data custodian, the Hong Kong Hospital Authority (HA), which manages the Clinical Data Analysis and Reporting System (CDARS), has not granted permission for public release. Researchers who meet the criteria for access to confidential data may apply for access to CDARS data for research purposes through the Hospital Authority Data Sharing Portal (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 14 MeSH terms, 1 funder, 39 references.
Cite
This paper
Li, Y., Chan, V. K. Y., Jit, M., Cheng, F. W. T., Yiu, H. H. E., Bishai, D. M., Craig, D., Chan, E. W. Y., Chan, S. S. M., & Li, X. (2026). Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study. PLoS medicine, 23(4), e1005047. https://
BibTeX
@article{li2026cost,
author = {Li, Yifan and Chan, Vivien Kin Yi and Jit, Mark and Cheng, Franco Wing Tak and Yiu, Hei Hang Edmund and Bishai, David Makram and Craig, Dawn and Chan, Esther Wai Yin and Chan, Sandra Sau Man and Li, Xue},
title = {{Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study}},
journal = {PLoS medicine},
year = {2026},
month = apr,
volume = {23},
number = {4},
pages = {e1005047},
publisher = {PLOS},
issn = {1549-1277},
doi = {10.1371/
url = {https://
pmid = {41990095},
pmcid = {PMC13120699}
}
RIS
TY - JOUR
AU - Li, Yifan
AU - Chan, Vivien Kin Yi
AU - Jit, Mark
AU - Cheng, Franco Wing Tak
AU - Yiu, Hei Hang Edmund
AU - Bishai, David Makram
AU - Craig, Dawn
AU - Chan, Esther Wai Yin
AU - Chan, Sandra Sau Man
AU - Li, Xue
TI - Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study
T2 - PLoS medicine
J2 - PLoS Med
PY - 2026
DA - 2026/
VL - 23
IS - 4
SP - e1005047
SN - 1549-1277
PB - PLOS
DO - 10.1371/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1371/
"type": "article-journal",
"title": "Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study",
"container-title": "PLoS medicine",
"author": [
{
"family": "Li",
"given": "Yifan"
},
{
"family": "Chan",
"given": "Vivien Kin Yi"
},
{
"family": "Jit",
"given": "Mark"
},
{
"family": "Cheng",
"given": "Franco Wing Tak"
},
{
"family": "Yiu",
"given": "Hei Hang Edmund"
},
{
"family": "Bishai",
"given": "David Makram"
},
{
"family": "Craig",
"given": "Dawn"
},
{
"family": "Chan",
"given": "Esther Wai Yin"
},
{
"family": "Chan",
"given": "Sandra Sau Man"
},
{
"family": "Li",
"given": "Xue"
}
],
"container-title-short":
"volume": "23",
"issue": "4",
"page": "e1005047",
"DOI": "10.1371/
"PMID": "41990095",
"PMCID": "PMC13120699",
"ISSN": "1549-1277",
"publisher": "PLOS",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
16
]
]
}
}
The tracing map gets a citation of its own once an author has validated it and it has a DOI.
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41467-023-42141-5 [code]
- Ketamine's acute effects on negative brain states are mediated through distinct altered states of consciousness in humans.Journal: Nature communicationsIn common: ggplot2, tidyverse, 2 references
- [2] doi:10.1192/bjp.2026.10664 [code]
- Early effects of a novel 5-HT&
lt;sub& gt;4& lt;/ sub& gt;R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study. Journal: The British journal of psychiatry : the journal of mental scienceIn common: data.table, ggplot2, tidyverse, depression, 1 reference - [3] doi:10.1038/s41467-026-71542-5 [code]
- Astrocyte fatty acid metabolism as a driver of risk for major depressive disorder.Journal: Nature communicationsIn common: data.table, ggplot2, tidyverse, depression, 1 reference
- [4] doi:10.1038/s41380-026-03485-8 [code]
- Positive bias in brain and behaviour as a mechanism of transcranial magnetic stimulation depression treatment.Journal: Molecular psychiatryIn common: ggplot2, tidyverse, depression, other, clinical / translational, 1 reference
- [5] doi:10.1016/j.brs.2026.103172 [code]
- Effects of personalized transcranial magnetic stimulation on social cognitive network functional connectivity in schizophrenia spectrum disorders: A double-blind, randomized, sham-controlled target engagement trial.Journal: Brain stimulationIn common: ggplot2, tidyverse, other, 1 reference
- [6] doi:10.1126/sciadv.ado6705 [code]
- Subthreshold repetitive transcranial magnetic stimulation induces cortical layer-, brain region-, and protocol-dependent neural plasticity.Journal: Science advancesIn common: ggplot2, tidyverse, other, 1 reference
- [7] doi:10.1038/s41380-024-02699-y [code]
- Markers of positive affect and brain state synchrony discriminate melancholic from non-melancholic depression using naturalistic stimuli.Journal: Molecular psychiatryIn common: ggplot2, tidyverse, depression, 1 reference
- [8] doi:10.1038/s41380-022-01725-1 [code]
- Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling.Journal: Molecular psychiatryIn common: ggplot2, tidyverse, depression, 1 reference
- [9] doi:10.1007/s10803-024-06244-2 [code]
- Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder.Journal: Journal of autism and developmental disordersIn common: depression, other, clinical / translational, 1 reference
- [10] doi:10.3389/fpsyt.2022.894473 [code]
- Baseline Clinical and Neuroimaging Biomarkers of Treatment Response to High-Frequency rTMS Over the Left DLPFC for Resistant Depression.Journal: Frontiers in psychiatryIn common: depression, other, clinical / translational, 1 reference
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Validate its tracing map
You validate the map as this page shows it: 2 repositories of the authors' code, each at its verified commit and with its license, 56 scripts, and 0 matches between paragraphs and code (see the Code and Map sections). It then receives a DOI on Zenodo, with you (your ORCID iD) and OSCR as its creators; the code itself is not deposited.
The map's fingerprint: sha256:4a88779dd542489a…
Add the badge to the code's README
If you are an author or a maintainer of this paper's code, you can add this badge. It says what OSCR knows of the paper (its code, its validated tracing map) and links the code to this page. Paste one of these snippets under the README's title. Keep the two marks around it, so that the badge can be replaced in place and is never added twice. OSCR changes nothing in your repository.
Markdown
<!-- oscr-badge:start -->
[](https://openscicode.org/badge/doi/10.1371/journal.pmed.1005047)
<!-- oscr-badge:end -->reStructuredText
.. oscr-badge:start
.. image:: https://openscicode.org/badge/doi/10.1371/journal.pmed.1005047.svg
:target: https://openscicode.org/badge/doi/10.1371/journal.pmed.1005047
:alt: OSCR
.. oscr-badge:endHTML
<!-- oscr-badge:start -->
<a href="https://openscicode.org/badge/doi/10.1371/journal.pmed.1005047"><img src="https://openscicode.org/badge/doi/10.1371/journal.pmed.1005047.svg" alt="OSCR"></a>
<!-- oscr-badge:end -->On GitHub, open the README, choose Edit (the pencil), paste the snippet under the title, then "Commit changes".
If you choose to, you can have the badge kept up to date for you, with oscr badge --write from the command line or with the GitHub Action in your repository's workflows. Every other form and option (a card, AsciiDoc, LaTeX, shields.io) is on the badge page.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Report a mismatch between the code and the paper · Report a code error (signed in)
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Report a reproduction failure (signed in)
Versions of its code: the releases of its code tied to a version of this paper (the preprint, the accepted manuscript, the version of record…), each with the tracing map versioned with it.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
